Evercore ISI downgraded Chinook Therapeutics (KDNY) to In Line from Outperform with a $40 price target after Novartis (NVS) agreed to acquire Chinook for $3.2B upfront plus contingent value rights, or CVRs, worth up to $320M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KDNY:
- Chinook Therapeutics downgraded to Hold from Buy at Stifel
- Chinook Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Chinook downgraded to Market Perform from Outperform at SVB Securities
- Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
- Lexicon has ‘only un-partnered asset’ in SGLT2i space, says Piper